TAK-861 Shows Promise in Phase 2b Narcolepsy Type 1 Trial

TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial.

Related Keywords

,Drug Administration ,Breakthrough Therapy ,Narcolepsy Type ,Wakefulness Test ,Epworth Sleepiness Scale ,Weekly Cataplexy Rate ,Toward Phase ,